NO20072255L - Sammensetning omfattende acetaminofen, koffein og valgfritt aspirin sammen med et alkalisk middel for forbedret absorpsjon - Google Patents

Sammensetning omfattende acetaminofen, koffein og valgfritt aspirin sammen med et alkalisk middel for forbedret absorpsjon

Info

Publication number
NO20072255L
NO20072255L NO20072255A NO20072255A NO20072255L NO 20072255 L NO20072255 L NO 20072255L NO 20072255 A NO20072255 A NO 20072255A NO 20072255 A NO20072255 A NO 20072255A NO 20072255 L NO20072255 L NO 20072255L
Authority
NO
Norway
Prior art keywords
composition
acetaminophen
caffeine
optional
alkaline agent
Prior art date
Application number
NO20072255A
Other languages
English (en)
Norwegian (no)
Inventor
Rong Liu
Michael Corbo
Jatin Desai
Gerard P Frunzi
Xiaohong Qi
Candice Y Choi
Rahul R Gandhi
Atef Z Boulos
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20072255L publication Critical patent/NO20072255L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20072255A 2004-10-28 2007-05-02 Sammensetning omfattende acetaminofen, koffein og valgfritt aspirin sammen med et alkalisk middel for forbedret absorpsjon NO20072255L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62281204P 2004-10-28 2004-10-28
PCT/US2005/038507 WO2006049978A1 (en) 2004-10-28 2005-10-26 Composition comprising acetaminophen, caffeine and optionally aspirin together with an alkiline agent fr enhanced absorption

Publications (1)

Publication Number Publication Date
NO20072255L true NO20072255L (no) 2007-07-18

Family

ID=35744599

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072255A NO20072255L (no) 2004-10-28 2007-05-02 Sammensetning omfattende acetaminofen, koffein og valgfritt aspirin sammen med et alkalisk middel for forbedret absorpsjon

Country Status (17)

Country Link
US (1) US20070298096A1 (de)
EP (1) EP1807068B1 (de)
JP (1) JP2008518914A (de)
CN (1) CN101048155A (de)
AR (1) AR051145A1 (de)
AT (1) ATE460930T1 (de)
AU (1) AU2005302618B2 (de)
BR (1) BRPI0520000A2 (de)
CA (1) CA2583517C (de)
DE (1) DE602005020048D1 (de)
MX (1) MX2007005121A (de)
NO (1) NO20072255L (de)
PE (1) PE20061125A1 (de)
PL (1) PL1807068T3 (de)
PT (1) PT1807068E (de)
RU (1) RU2398571C2 (de)
WO (1) WO2006049978A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0607085D0 (en) * 2006-04-07 2006-05-17 Smithkline Beecham Corp Novel compositions
CN100417385C (zh) * 2006-09-26 2008-09-10 林星 一种用于治疗外伤的外用制剂
GB0707489D0 (en) * 2007-04-18 2007-05-23 Renaissance Pharma Compounds
CN101596163B (zh) * 2008-06-06 2012-06-27 康美保宁（四川）制药有限公司 阿咖酚微丸制剂及其制备方法
GB0813929D0 (en) 2008-07-30 2008-09-03 Glaxo Group Ltd Novel method
CN102861040B (zh) * 2012-08-02 2014-04-23 广东环球制药有限公司 含有阿司匹林、对乙酰氨基酚和咖啡因的药物组合物及其制备方法
CN102949401A (zh) * 2012-09-06 2013-03-06 广东九明制药有限公司 对乙酰氨基酚、乙酰水杨酸和咖啡因组合物及其制备工艺
US10124005B1 (en) * 2017-12-15 2018-11-13 Lisa Josette Myslinski Multisymptom migraine combination medication
CN110711197B (zh) * 2018-07-12 2023-11-24 北京恒润泰生医药科技有限公司 阿司匹林和对乙酰氨基酚的分子复合物加咖啡因,其制备,活性及应用
CN108853124A (zh) * 2018-08-15 2018-11-23 康美保宁（四川）制药有限公司 一种阿咖酚制剂及其制剂方法
GB202007670D0 (en) * 2020-05-22 2020-07-08 Glaxosmithkline Consumer Healthcare Holdings Us Llc Pharmaceutical composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4294819A (en) * 1980-08-18 1981-10-13 Bristol-Myers Company Alkaline analgesic capsule
CA1182049A (en) * 1981-07-13 1985-02-05 Francis J. Sterbenz Apap antacid composition
US5296241A (en) * 1991-04-03 1994-03-22 Brimberg Barnett J Therapeutic composition and method of using same for treatment of hangover
JP3122748B2 (ja) * 1991-11-29 2001-01-09 ライオン株式会社 イブプロフェン含有解熱鎮痛剤
JP3172749B2 (ja) * 1992-02-17 2001-06-04 ライオン株式会社 イブプロフェン含有製剤
JPH06227995A (ja) * 1993-02-03 1994-08-16 Takeda Chem Ind Ltd 安定化された固型製剤
JPH07206689A (ja) * 1994-01-21 1995-08-08 Barnett Lab Ltd 治療組成物および宿酔の治療のためのこの組成物の使用法
DE19502789A1 (de) * 1995-01-28 1996-08-01 Dirk Krischenowski Arzneimittel
GB9704524D0 (en) * 1997-03-05 1997-04-23 Smithkline Beecham Plc Composition
US5972916A (en) * 1997-07-14 1999-10-26 Bristol-Myers Squibb Company Compositions containing the nonprescription combination of acetaminophen, aspirin and caffeine to alleviate the pain and symptoms of migraine
JP2002012557A (ja) * 2000-06-28 2002-01-15 Lion Corp 内服薬組成物
KR20040004638A (ko) * 2001-05-25 2004-01-13 에스에스 세야쿠 가부시키 가이샤 의약 조성물
JP4553552B2 (ja) * 2003-01-08 2010-09-29 日東薬品工業株式会社 生体リズム応用キット

Also Published As

Publication number Publication date
CA2583517C (en) 2013-06-04
PL1807068T3 (pl) 2010-08-31
EP1807068A1 (de) 2007-07-18
PT1807068E (pt) 2010-04-19
US20070298096A1 (en) 2007-12-27
PE20061125A1 (es) 2006-11-08
RU2007119641A (ru) 2008-12-10
EP1807068B1 (de) 2010-03-17
AR051145A1 (es) 2006-12-20
RU2398571C2 (ru) 2010-09-10
AU2005302618B2 (en) 2009-10-22
CN101048155A (zh) 2007-10-03
ATE460930T1 (de) 2010-04-15
DE602005020048D1 (de) 2010-04-29
JP2008518914A (ja) 2008-06-05
AU2005302618A1 (en) 2006-05-11
WO2006049978A1 (en) 2006-05-11
CA2583517A1 (en) 2006-05-11
MX2007005121A (es) 2007-06-22
BRPI0520000A2 (pt) 2009-04-07

Similar Documents

Publication Publication Date Title
NO20072255L (no) Sammensetning omfattende acetaminofen, koffein og valgfritt aspirin sammen med et alkalisk middel for forbedret absorpsjon
BRPI0514474A (pt) multiparticulados
DK2029529T3 (da) Substitueret pyrrolidinone som inhibitor af 11-beta-hydroxysteroiddehydrogenase 1
NO20060416L (no) Ny anvendelse I
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
NO20081790L (no) Topiske formuleringer
EA200801826A1 (ru) Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения
ATE471311T1 (de) Inhibitoren von11-beta- hydroxysteroiddehydrogenase 1
EA200870462A1 (ru) Производные бифениламидлактама в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1
NO20073699L (no) Stabile protaglandin-inneholdende preparater
EA200870472A1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
BRPI0510842A (pt) composição e seu uso
EA201070656A1 (ru) Способ задержки начала проявления клинически определенного рассеянного склероза
RS52110B (en) DIPEPTIDIL PEPTIDASE INHIBITORS FOR TREATMENT OF DIABETES
BRPI0513944A (pt) forma substancialmente pura de um composto de quinazolina, uso de um composto de quinazolina e composição
DK1735296T3 (da) Materialer og fremgangsmåder til behandling af koagulationslidelser
NO20075361L (no) Fremgangsmate og preparat for behandling av slimhinneforstyrrelser
DK1225881T3 (da) Anvendelsen af dapoxetin, en hurtigt-virkende selektiv serotonin genoptagelseshæmmer, til behandling af seksuel dysfunktion
NO20083426L (no) IPBC-inneholdene koacervater
WO2006107411A3 (en) Formulations containing fenofibrate and surfacant mixture
DK1296972T3 (da) Arylmethylamin-derivater til anvendelse som tryptaseinhibitorer
BRPI0615046B8 (pt) uso de um composto
CL2007000345A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de uno o mas agentes terapeuticos y una cantidad mejoradora de la absorcion intestinal de uno o mas agonistas de receptores de zonulina/zot; y uso de la composicion para tratar la diabetes.
ATE468098T1 (de) Topische stabilisierte dosierungsformen für prostaglandin e-verbindungen
ATE531703T1 (de) Benzochromenderivate

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application